Fintel reports that on January 22, 2025, RBC Capital downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) ...
RBC Capital analyst Brian Abrahams maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) on January 21 and set a price target ...
RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte (INCY – Research Report) on January 21 and set a price target of $70.00.
CF Industries Holdings, Inc. (CF) stock saw a decline, ending the day at $93.66 which represents a decrease of $-3.35 or -3.45% from the prior close of $97.01. The stock opened at $95.5 and touched a ...
The Unilever share price looked like it was about to kick into gear... but it's idling again. Harvey Jones now wonders if his ...
However, its 2025 costs and capital expenditure guidance exceeded analyst expectations as well as its own previous guidance. For full-year 2025, Hochschild expects capital expenditure between $197 ...
GE Vernova's shares hit a new intraday high of over $407 on Tuesday, bolstered by investor confidence despite recent political developments. RBC Capital analysts ...